59
-13.24%
Close of 9 Nov 2026, in JPY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About SymBio Pharmaceuticals
Its shares trade on Tokyo Stock Exchange under the ticker 4582.T. It has been listed since 20 October 2011. In the fiscal year to 31 December 2025, it reported revenue of ¥1.31bn and a net loss of ¥4.78bn. At that date it held total assets of ¥3.87bn and shareholders' equity of ¥1.27bn.
SymBio Pharmaceuticals Ltd. engages in the pharmaceutical business. The company is headquartered in Minato-Ku, Tokyo-To. The company went IPO on 2011-10-20. Along with medicine specialists, contract research organizations (CROs) and other pharmaceutical companies, the Company is engaged in the design and operation of clinical tests, the manufacture and sale of new drugs specializing in three therapeutic areas: cancer, blood diseases and autoimmune diseases. The firm develops new medicines using chemical compounds proofed by preclinical tests and clinical tests. The firm manufactures and sells medicines through domestic and foreign pharmaceutical companies. The firm's pipelines include anticancer drugs, such as SyB L-0501, SyB L-1101 and SyB C-1101.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 20 Oct 2011
- Employees
- 107
- Website
- symbiopharma.com ↗
Leadership
Pay as last reported
- Mr. Fuminori YoshidaPresident, Executive President, Chief Executive Officer, Representative Director, since 2005
- Mr. Noritaka NarimiyaManaging Executive Officer, Chief Financial Officer
- Mr. Ken TaguchiExecutive Vice President, Chief Operating Officer
- Mr. Koji FukushimaExecutive Officer, Deputy Chief Medical Officer
- Mr. Masatoshi HazamaExecutive Officer, CSO
- Mr. Paul MarstonExecutive Officer, General Counsel
- Mr. Bruce ChesonIndependent Director
- Mr. Eiji EbinumaIndependent Director
- Mr. Toshio ImabeppuIndependent Director
- Mr. Shigetoshi MatsumotoIndependent Director
- Dr. George MorstynIndependent Director
- Mr. Koichi ShimomuraIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- SymBio Pharmaceuticals Ltd has several strengths that contribute to its competitive advantage in the pharmaceutical industry. These strengths include:
Weaknesses
- Despite its strengths, SymBio Pharmaceuticals Ltd also faces certain weaknesses that need to be addressed to optimize its performance and market position. These weaknesses include:
Opportunities
- SymBio Pharmaceuticals Ltd can capitalize on various opportunities to further enhance its market position and profitability. These opportunities include:
Threats
- SymBio Pharmaceuticals Ltd operates in a dynamic and competitive industry, which presents certain threats that may impact its performance and profitability. These threats include:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.